- Home
- LNSR vs UNCY Comparison
LNSR vs UNCY Comparison
Compare LNSR & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNSR
- UNCY
- Stock Information
- Founded
- LNSR 2004
- UNCY 2016
- Country
- LNSR United States
- UNCY United States
- Employees
- LNSR N/A
- UNCY N/A
- Industry
- LNSR Medical Electronics
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- LNSR Health Care
- UNCY Health Care
- Exchange
- LNSR Nasdaq
- UNCY Nasdaq
- Market Cap
- LNSR 63.4M
- UNCY 58.7M
- IPO Year
- LNSR N/A
- UNCY 2021
- Fundamental
- Price
- LNSR $14.06
- UNCY $0.55
- Analyst Decision
- LNSR Hold
- UNCY Strong Buy
- Analyst Count
- LNSR 1
- UNCY 3
- Target Price
- LNSR $15.00
- UNCY $6.50
- AVG Volume (30 Days)
- LNSR 248.3K
- UNCY 925.3K
- Earning Date
- LNSR 05-08-2025
- UNCY 05-12-2025
- Dividend Yield
- LNSR N/A
- UNCY N/A
- EPS Growth
- LNSR N/A
- UNCY N/A
- EPS
- LNSR N/A
- UNCY N/A
- Revenue
- LNSR $53,494,000.00
- UNCY N/A
- Revenue This Year
- LNSR $29.95
- UNCY N/A
- Revenue Next Year
- LNSR $29.35
- UNCY $888.72
- P/E Ratio
- LNSR N/A
- UNCY N/A
- Revenue Growth
- LNSR 26.87
- UNCY N/A
- 52 Week Low
- LNSR $2.67
- UNCY $0.20
- 52 Week High
- LNSR $17.31
- UNCY $1.60
- Technical
- Relative Strength Index (RSI)
- LNSR 52.73
- UNCY 40.61
- Support Level
- LNSR $14.06
- UNCY $0.60
- Resistance Level
- LNSR $14.25
- UNCY $0.65
- Average True Range (ATR)
- LNSR 0.73
- UNCY 0.05
- MACD
- LNSR -0.29
- UNCY -0.01
- Stochastic Oscillator
- LNSR 1.22
- UNCY 3.86
About LNSR LENSAR Inc.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency and reproducibility by providing imaging, simplified procedure planning, efficient design and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The consumable portion of the system consists of a disposable patient interface device, or PID, kit and a procedure license. Each procedure on each system requires the use of a PID kit.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.